RxDoctor Payments Data

Bonny Moore, MD

Hematology & Oncology · Fredericksburg, VANPI 1902048051

Payments from drug & device makers

$6,797in general payments, 2019–2025

Across 339 payments — averaging $20.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$795
  • Novartis$704
  • Johnson & Johnson$466
  • Gilead$389
  • E.r. Squibb & Sons, L.L.C.$377
  • Seagen Inc.$359
  • plus $4K from 54 others

What the payments were for

  • Food & beverage$6,19691%
  • Education$6009%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer51$795
Novartis48$704
Johnson & Johnson(2 entities)22$466
Gilead(2 entities)19$389
E.r. Squibb & Sons, L.L.C.16$377
Seagen Inc.7$359
Regeneron Healthcare Solutions, Inc.10$289
AstraZeneca(2 entities)13$263
GSK9$187
Merck9$179
Genentech USA, Inc.9$175
Array Biopharma Inc7$147
Amgen5$137
Bristol Myers Squibb8$137
Eisai Inc.5$109
Pharmacyclics LLC, An Abbvie Company2$99
Incyte Corporation5$92
Rigel Pharmaceuticals, Inc.4$89
Astellas Pharma US Inc6$88
Mirati Therapeutics, Inc.4$87
Lilly USA, LLC5$83
Adaptive Biotechnologies Corporation4$83
Bayer3$73
Takeda Pharmaceuticals U.S.A., Inc.5$73
Daiichi Sankyo Inc.3$70
AbbVie3$70
Sanofi3$66
Pharmaessentia USA Corporation2$64
EMD Serono, Inc.3$64
Blue Earth Diagnostics3$64
CTI Biopharma Corp.2$49
Puma Biotechnology, Inc.3$49
Jazz Pharmaceuticals Inc.3$47
Foundation Medicine, Inc.2$40
EUSA Pharma (US) LLC2$38
Aurobindo Pharma USA, Inc.2$38
Heron Therapeutics, Inc.2$36
ASD Specialty Healthcare, LLC1$32
Sirtex Medical Inc1$30
Ipsen Biopharmaceuticals, Inc1$29
Coherus Oncology, Inc.1$29
Morphosys, US Inc.2$28
Immunogen, Inc.1$28
Karyopharm Therapeutics Inc.1$25
Caris MPI, Inc.1$25
Pharmacosmos Therapeutics Inc.1$24
Genmab U.S., Inc.1$24
Deciphera Pharmaceuticals Inc.1$24
Menarini Silicon Biosystems, Inc.1$24
Novocure Inc.1$23
Taiho Oncology, Inc.1$22
Sun Pharmaceutical Industries Inc.1$21
Exelixis Inc.1$21
Dendreon Pharmaceuticals LLC1$21
Pharming Healthcare, Inc.1$20
Servier Pharmaceuticals LLC1$19
Cardiovascular Systems Inc.1$19
Tesaro, Inc.1$18
Myovant Sciences Inc.1$16
Partner Therapeutics, Inc.1$16

How this compares

$6,797 in reported general payments places this provider in the 60th percentile of 293 hematology & oncology providers in Virginia.

See all hematology & oncology providers in Virginia

Medicare billing

Part B allowed, 2024
$6,673,965
Medicare patients
1,600
Services billed
350,160

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BrukinsaZanubrutinib13$199,060
ImbruvicaIbrutinib13$198,590
XtandiEnzalutamide14$193,115
CalquenceAcalabrutinib Maleate12$180,409
EliquisApixaban139$151,488
XareltoRivaroxaban56$55,530
Letrozole152$3,324
Exemestane18$2,851
Anastrozole91$1,535
Mirtazapine38$922
Hydroxyurea28$880
Ondansetron Hcl14$528
Prochlorperazine Maleate23$519
Hydroxyzine Hcl22$457
Levothyroxine Sodium27$408

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Pharmacyclics LLC, An Abbvie CompanyImbruvica$99$198,59013 claims
Astellas Pharma US IncXtandi$88$193,11514 claims
AstraZenecaCalquence$263$180,40912 claims
PfizerEliquis$795$151,488139 claims
Johnson & JohnsonXarelto$466$55,53056 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 293 hematology & oncology providers in Virginia.

Other hematology & oncology in Fredericksburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →